Surgery Today

, Volume 48, Issue 1, pp 66–72 | Cite as

Phase III trial comparing UFT + PSK to UFT + LV in stage IIB, III colorectal cancer (MCSGO-CCTG)

  • Yasuhiro Miyake
  • Junichi Nishimura
  • Takeshi KatoEmail author
  • Masataka Ikeda
  • Masaki Tsujie
  • Taishi Hata
  • Ichiro Takemasa
  • Tsunekazu Mizushima
  • Hirofumi Yamamoto
  • Mitsugu Sekimoto
  • Riichiro Nezu
  • Yuichiro Doki
  • Masaki Mori
  • Multi-center Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MCSGO)
Original Article



Oral adjuvant uracil and tegafur plus leucovorin (UFT/LV) is not inferior to standard weekly fluorouracil and folinate for stage II/III colon cancer. However, protein-bound polysaccharide K (PSK) has been evaluated as postoperative adjuvant therapy for colorectal cancer. This report is the first of MCSGO-CCTG, which compared UFT/LV to UFT/PSK as adjuvant chemotherapy for stage IIB or III colorectal cancer in patients who had undergone Japanese D2/D3 lymph node dissection.


The primary endpoint was the 3-year disease-free survival (DFS). A randomized non-inferiority study compared UFT/LV to UFT/PSK. The overall survival, adverse events, compliance, and quality of life were also investigated as the secondary endpoints.


Between March 2006 and December 2010, 357 patients were randomized to UFT/PSK (n = 178) or UFT/LV (n = 179) (median age 65 years, colon/rectum 67.4/32.6%, stage IIB/IIIA/IIIB/IIIC 11.1/15.7/55.0/18.2%). The 3-year DFS rate was 82.3% in those receiving UFT/LV and 72.1% in those receiving UFT/PSK. The non-inferiority of UFT/PSK adjuvant therapy to UFT/LV therapy was not verified (−9.06%, 90% confidence interval −17.06 to −1.06%). The 3-year overall survival rate was 95.4% in those receiving UFT/LV and 90.7% in those receiving UFT/PSK.


As adjuvant chemotherapy for stage IIB and III colorectal cancer patients, UFT/PSK adjuvant therapy was not non-inferior to UFT/LV therapy with respect to the DFS.


Colorectal cancer Adjuvant therapy Protein-bound polysaccharide K UFT/LV Stage IIB Stage III 



This study was supported by a Grant from The Supporting Center for Clinical Research and Education (Osaka, Japan), a nonprofit foundation. We thank Dr. Yuko Ohno and Makoto Fujii for the statistical analysis. We also thank the patients for their participation in this study and the study management teams and staff at the individual study sites.

Compliance with ethical standards

Conflict of interest

Yasuhiro Miyake, Junichi Nishimura, and other co-authors have no conflict of interest.


  1. 1.
    Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322(6):352–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Colvin H, Mizushima T, Eguchi H, Takiguchi S, Doki Y, Mori M. Gastroenterological surgery in Japan: the past, the present and the future. Ann Gastroenterol Surg. 2017;1:5–10.CrossRefGoogle Scholar
  3. 3.
    Hamaguchi T, Shirao K, Moriya Y, Yoshida S, Kodaira S, Ohashi Y, et al. Final results of randomized trials by the National Surgical Adjuvant Study of Colorectal Cancer (NSAS-CC). Cancer Chemother Pharmacol. 2011;67(3):587–96.CrossRefPubMedGoogle Scholar
  4. 4.
    Sakamoto J, Hamada C, Yoshida S, Kodaira S, Yasutomi M, Kato T, et al. An individual patient data meta-analysis of adjuvant therapy with uracil-tegafur (UFT) in patients with curatively resected rectal cancer. Br J Cancer. 2007;96(8):1170–7.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Lembersky BC, Wieand HS, Petrelli NJ, O’Connell MJ, Colangelo LH, Smith RE, et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol. 2006;24(13):2059–64.CrossRefPubMedGoogle Scholar
  6. 6.
    Shimada Y, Hamaguchi T, Mizusawa J, Saito N, Kanemitsu Y, Takiguchi N, et al. Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final results of JCOG0205. Eur J Cancer. 2014;50(13):2231–40.CrossRefPubMedGoogle Scholar
  7. 7.
    Ward SE, Kaltenthaler E, Cowan J, Marples M, Orr B, Seymour MT. The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. Br J Cancer. 2006;95(1):27–34.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Fisher M, Yang LX. Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy. Anticancer Res. 2002;22(3):1737–54.PubMedGoogle Scholar
  9. 9.
    Lu H, Yang Y, Gad E, Wenner CA, Chang A, Larson ER, et al. Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells. Clin Cancer Res. 2011;17(1):67–76.CrossRefPubMedGoogle Scholar
  10. 10.
    Ono Y, Hayashida T, Konagai A, Okazaki H, Miyao K, Kawachi S, et al. Direct inhibition of the transforming growth factor-beta pathway by protein-bound polysaccharide through inactivation of Smad2 signaling. Cancer Sci. 2012;103(2):317–24.CrossRefPubMedGoogle Scholar
  11. 11.
    Hirahara N, Fujioka M, Edamatsu T, Fujieda A, Sekine F, Wada T, et al. Protein-bound polysaccharide-K (PSK) induces apoptosis and inhibits proliferation of promyelomonocytic leukemia HL-60 cells. Anticancer Res. 2011;31(9):2733–8.PubMedGoogle Scholar
  12. 12.
    Jimenez-Medina E, Berruguilla E, Romero I, Algarra I, Collado A, Garrido F, et al. The immunomodulator PSK induces in vitro cytotoxic activity in tumour cell lines via arrest of cell cycle and induction of apoptosis. BMC Cancer. 2008;8:78.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Ito K, Nakazato H, Koike A, Takagi H, Saji S, Baba S, et al. Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. A randomized controlled trial for 7-year follow-up. Int J Colorectal Dis. 2004;19(2):157–64.CrossRefPubMedGoogle Scholar
  14. 14.
    Maehara Y, Moriguchi S, Sakaguchi Y, Emi Y, Kohnoe S, Tsujitani S, et al. Adjuvant chemotherapy enhances long-term survival of patients with advanced gastric cancer following curative resection. J Surg Oncol. 1990;45(3):169–72.CrossRefPubMedGoogle Scholar
  15. 15.
    Niimoto M, Hattori T, Tamada R, Sugimachi K, Inokuchi K, Ogawa N. Postoperative adjuvant immunochemotherapy with mitomycin C, futraful and PSK for gastric cancer. An analysis of data on 579 patients followed for 5 years. Jpn J Surg. 1988;18(6):681–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Ohwada S, Ikeya T, Yokomori T, Kusaba T, Roppongi T, Takahashi T, et al. Adjuvant immunochemotherapy with oral tegafur/uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study. Br J Cancer. 2004;90(5):1003–10.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Torisu M, Hayashi Y, Ishimitsu T, Fujimura T, Iwasaki K, Katano M, et al. Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer. Cancer Immunol Immunother. 1990;31(5):261–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Ohwada S, Kawate S, Ikeya T, Yokomori T, Kusaba T, Roppongi T, et al. Adjuvant therapy with protein-bound polysaccharide K and tegafur uracil in patients with stage II or III colorectal cancer: randomized, controlled trial. Dis Colon Rectum. 2003;46(8):1060–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Sadahiro S, Suzuki T, Maeda Y, Tanaka A, Kamijo A, Murayama C, et al. Effects of preoperative immunochemoradiotherapy and chemoradiotherapy on immune responses in patients with rectal adenocarcinoma. Anticancer Res. 2010;30(3):993–9.PubMedGoogle Scholar
  20. 20.
    Farrington CP, Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med. 1990;9(12):1447–54.CrossRefPubMedGoogle Scholar
  21. 21.
    Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–51.CrossRefPubMedGoogle Scholar
  22. 22.
    Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29(11):1465–71.CrossRefPubMedGoogle Scholar
  23. 23.
    Kuebler JP, Wieand HS, O’Connell MJ, Smith RE, Colangelo LH, Yothers G, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25(16):2198–204.CrossRefPubMedGoogle Scholar
  24. 24.
    Mieno H, Yamashita K, Hosoda K, Moriya H, Higuchi K, Azuma M, et al. Conversion surgery after combination chemotherapy of docetaxel, cisplatin and S-1 (DCS) for far-advanced gastric cancer. Surg Today. 2017. doi: 10.1007/s00595-017-1512-z.PubMedGoogle Scholar
  25. 25.
    Kodera Y. Neoadjuvant chemotherapy for gastric adenocarcinoma in Japan. Surg Today. 2017. doi: 10.1007/s00595-017-1473-2.PubMedGoogle Scholar
  26. 26.
    Honma Y, Yamada Y, Terazawa T, Takashima A, Iwasa S, Kato K, et al. Feasibility of neoadjuvant S-1 and oxaliplatin followed by surgery for resectable advanced gastric adenocarcinoma. Surg Today. 2016;46(9):1076–82.CrossRefPubMedGoogle Scholar
  27. 27.
    Beppu N, Yoshie H, Kimura F, Aihara T, Doi H, Kamikonya N, et al. The short-term outcomes of induction SOX (S-1 + oxaliplatin) ± cetuximab chemotherapy followed by short-course chemoradiotherapy in patients with poor-risk locally advanced rectal cancer. Surg Today. 2016;46(10):1123–31.CrossRefPubMedGoogle Scholar
  28. 28.
    Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol. 2012;17(1):1–29.CrossRefPubMedGoogle Scholar
  29. 29.
    Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Ooshiro M, Sugishita YI, Tanaka H, Koide K, Nagashima M, Katoh R. Regulation of perioperative immunological changes following laparotomy: effects of biological response modifier (BRM) on surgical stress. Immunol Lett. 2004;93(1):33–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Okuzawa M, Shinohara H, Kobayashi T, Iwamoto M, Toyoda M, Tanigawa N. PSK, a protein-bound polysaccharide, overcomes defective maturation of dendritic cells exposed to tumor-derived factors in vitro. Int J Oncol. 2002;20(6):1189–95.PubMedGoogle Scholar

Copyright information

© Springer Japan KK 2017

Authors and Affiliations

  • Yasuhiro Miyake
    • 1
  • Junichi Nishimura
    • 2
  • Takeshi Kato
    • 3
    Email author
  • Masataka Ikeda
    • 4
  • Masaki Tsujie
    • 5
  • Taishi Hata
    • 2
  • Ichiro Takemasa
    • 2
  • Tsunekazu Mizushima
    • 2
  • Hirofumi Yamamoto
    • 2
  • Mitsugu Sekimoto
    • 4
  • Riichiro Nezu
    • 1
  • Yuichiro Doki
    • 2
  • Masaki Mori
    • 2
  • Multi-center Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MCSGO)
  1. 1.Department of SurgeryNishinomiya Municipal HospitalNishinomiyaJapan
  2. 2.Department of Gastroenterological SurgeryOsaka University Graduate School of MedicineSuitaJapan
  3. 3.Department of SurgeryKansai Rosai HospitalAmagasakiJapan
  4. 4.Department of SurgeryNational Hospital Organization, Osaka National HospitalOsakaJapan
  5. 5.Department of SurgeryHyogo Prefectural Nishinomiya HospitalNishinomiyaJapan

Personalised recommendations